HealthIndia approves Novo Nordisk’s Wegovy for fatty liver disease
India’s drug regulator has approved Danish pharmaceutical company Novo Nordisk’s obesity medicine Wegovy for treating metabolic dysfunction-associated steatohepatitis, known as MASH. Novo Nordisk said the decision was announced on Friday. MASH is described as a serious form of fatty liver disease. The approval adds treatment of the condition to Wegovy’s uses in India.
R
India approves Novo Nordisk’s Wegovy for fatty liver disease
Health